May 16th 2025
A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
J&J Receives EC Conditional Approval for its First Cell Therapy Product for Multiple Myeloma
June 10th 2022The European Commission has granted conditional marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for CARVYKTI (ciltacabtagene autoleucel), a cell therapy for treating multiple myeloma.
EC Approves Bristol Myers Squibb’s Opdivo in Second-Line Treatment of Esophageal Cancer
November 24th 2020The EC’s approval was based on positive results from a Phase III clinical trial that demonstrated a statistically significant and clinically meaningful improvement in patients compared to chemotherapy.